Optical coherence tomography (OCT) is a non-destructive imaging tool that provides high-resolution cross-sectional images of drug formulations. It is used to evaluate the uniformity of the coating, detect defects and characterize multilayer structures in solid dosage forms. Widespread adoption of OCT is hindered by a lack of pharmacopoeial monographs and specific regulatory guidelines. In recent years, regulatory interest in advanced analytics has grown, leading to method validation, quality-by-design (QbD) compliance, and Good Manufacturing Practice (GMP) compliance. The article provides insight into the development, implementation and regulatory evaluation of OCT in the pharmaceutical industry. It examines the implementation process, the evolving regulatory framework, and practical considerations for OCT adoption. The pharmaceutical industry is moving towards greater engagement with OCTs due to growing regulatory interest. It emphasizes the need for standardization and incorporation of OCTs into regulatory frameworks through stakeholder collaboration.